首页> 外文期刊>Cancer Cell >The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression
【24h】

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression

机译:Polycomb阻遏物复合物1通过协调茎和免疫抑制来驱动双阴性前列腺癌转移

获取原文
获取原文并翻译 | 示例
           

摘要

The mechanisms that enable immune evasion at metastatic sites are poorly understood. We show that the Polycomb Repressor Complex 1 (PRC1) drives colonization of the bones and visceral organs in double-negative prostate cancer (DNPC). In vivo genetic screening identifies CCL2 as the top prometastatic gene induced by PRC1. CCL2 governs self-renewal and induces the recruitment of M2-like tumor-associated macrophages and regulatory T cells, thus coordinating metastasis initiation with immune suppression and neoangiogenesis. A catalytic inhibitor of PRC1 cooperates with immune checkpoint therapy to reverse these processes and suppress metastasis in genetically engineered mouse transplantation models of DNPC. These results reveal that PRC1 coordinates stemness with immune evasion and neoangiogenesis and point to the potential clinical utility of targeting PRC1 in DNPC.
机译:使转移位点的免疫逃避能够理解的机制尚不清楚。 我们表明Polycomb阻遏物复合体1(PRC1)在双阴性前列腺癌(DNPC)中驱动骨骼和内脏器官的定植。 体内遗传筛查鉴定CCL2作为PRC1诱导的顶部突腓抑制基因。 CCL2治理自我更新,诱导募集M2样肿瘤相关的巨噬细胞和调节T细胞,从而协调与免疫抑制和新谐振发生的转移引发。 PRC1的催化抑制剂与免疫检查点疗法配合,以逆转这些过程并抑制DNPC的转基因小鼠移植模型中的转移。 这些结果表明,PRC1与免疫逃逸和新谐振发生的茎坐标,并指向DNPC中靶向PRC1的潜在临床效用。

著录项

  • 来源
    《Cancer Cell》 |2019年第2期|共27页
  • 作者单位

    Mem Sloan Kettering Canc Ctr Mol Pharmacol Program New York NY 10065 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

    Chinese Acad Sci Inst Zool State Key Lab Stem Cell &

    Reprod Biol Beijing 100101 Peoples R China;

    Mem Sloan Kettering Canc Ctr Mol Pharmacol Program New York NY 10065 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

    Mem Sloan Kettering Canc Ctr Dept Med New York NY 10065 USA;

    Mem Sloan Kettering Canc Ctr Canc Biol &

    Genet Program New York NY 10065 USA;

    Mem Sloan Kettering Canc Ctr Organ Synth Core Facil New York NY 10065 USA;

    Univ Texas MD Anderson Canc Ctr Dept Genitourinary Oncol Houston TX 77054 USA;

    Univ Texas MD Anderson Canc Ctr Dept Genitourinary Oncol Houston TX 77054 USA;

    Mem Sloan Kettering Canc Ctr Mol Pharmacol Program New York NY 10065 USA;

    Weill Cornell Med Coll Dept Med MSKCC Genitourinary Oncol Serv New York NY 10065 USA;

    Mem Sloan Kettering Canc Ctr Organ Synth Core Facil New York NY 10065 USA;

    Univ Texas MD Anderson Canc Ctr Dept Canc Biol Unit 1906 POB 301429 Houston TX 77030 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号